Merck (MRK) said Tuesday it has entered an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals for HRS-5346, an oral lipoprotein(a) inhibitor in phase 2 trials in China for cardiovascular disease.
Under the deal, Merck will have global rights to develop, manufacture, and commercialize HRS-5346, excluding the Greater China region, with Hengrui receiving a $200 million upfront payment, potential milestone payments up to $1.77 billion, and royalties on sales, the companies said.
The transaction, subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other conditions, is expected to close in Q2, Merck added.
Merck expects to record a pre-tax charge of $200 million, or $0.06 per share, in the quarter the deal closes, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.